We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+37.02%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$390M
AUM Growth
+$12.6M
Cap. Flow
-$64M
Cap. Flow %
-16.4%
Top 10 Hldgs %
30.29%
Holding
100
New
16
Increased
29
Reduced
38
Closed
17

Top Buys

Rank Stock Value
1
SDGR icon
Schrodinger
SDGR
+$6.67M
2
ARWR icon
Arrowhead Research
ARWR
+$4.3M
3
DXCM icon
DexCom
DXCM
+$4.27M
4
AVTR icon
Avantor
AVTR
+$3.89M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$3.76M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$12.7M
2
MRK icon
Merck
MRK
+$10.4M
3
AXNX
Axonics, Inc. Common Stock
AXNX
+$9.03M
4
MASI
Masimo
MASI
+$8.26M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.12M

Sector Composition

Rank Sector Weight
1 Healthcare 92.05%
2 Technology 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EIDX
51
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$2.84M 0.73%
21,609
-19,482
-47% -$1.72M
IMVT icon
52
Immunovant
IMVT
$8.8B
$2.81M 0.72%
60,781
-89,370
-60% -$4.13M
AXSM icon
53
Axsome Therapeutics
AXSM
$11.2B
$2.51M 0.64%
30,758
-4,252
-12% -$318K
TRIL
54
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.42M 0.62%
164,585
-210,478
-56% -$3.04M
ETNB
55
DELISTED
89bio
ETNB
$2.36M 0.6%
96,673
-13,327
-12% -$341K
BMRN icon
56
BioMarin Pharmaceuticals
BMRN
$13.6B
$2.19M 0.56%
+25,000
New +$1.98M
SDC
57
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
$2.1M 0.54%
175,691
-184,309
-51% -$2.09M
BCEL
58
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.04M 0.52%
126,258
+91,258
+261% +$1.37M
KALA icon
59
KALA BIO
KALA
$17.1M
$1.85M 0.47%
109
-15
-12% -$282K
ONCT
60
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$1.85M 0.47%
+18,839
New +$1.19M
TECX
61
Tectonic Therapeutic
TECX
$720M
$1.69M 0.43%
10,085
-3,300
-25% -$587K
SURF
62
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$1.62M 0.42%
175,792
-24,227
-12% -$211K
OM icon
63
Outset Medical
OM
$84.6M
$1.6M 0.41%
1,881
+1,414
+303% +$1.09M
CRIS icon
64
Curis
CRIS
$3.49M
$1.6M 0.41%
+488
New +$586K
CSTL icon
65
Castle Biosciences
CSTL
$960M
$1.53M 0.39%
22,831
-7,172
-24% -$389K
MTEM
66
DELISTED
Molecular Templates, Inc.
MTEM
$1.5M 0.39%
10,674
-7,189
-40% -$1.06M
MDGL icon
67
Madrigal Pharmaceuticals
MDGL
$12.4B
$1.44M 0.37%
12,976
-5,235
-29% -$640K
NEPH icon
68
Nephros
NEPH
$47.4M
$1.43M 0.37%
167,048
-74,363
-31% -$502K
PROF
69
Profound Medical
PROF
$252M
$1.42M 0.36%
69,049
-951
-1% -$17.5K
KNSA icon
70
Kiniksa Pharmaceuticals
KNSA
$6.1B
$1.32M 0.34%
+75,000
New +$1.32M
AUPH icon
71
Aurinia Pharmaceuticals
AUPH
$2.06B
$1.24M 0.32%
89,503
-40,809
-31% -$594K
GYRE icon
72
Gyre Therapeutics
GYRE
$706M
$1.19M 0.31%
25,221
-2,576
-9% -$112K
FBRX icon
73
Forte Biosciences
FBRX
$1.57B
$1.13M 0.29%
1,244
+744
+149% +$699K
ALT icon
74
Altimmune
ALT
$570M
$1.13M 0.29%
+100,000
New +$1.18M
BLRX
75
BioLineRX
BLRX
$11.7M
$1.08M 0.28%
+10,699
New +$935K
1 2
3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Parkman Healthcare Partners held 100 positions worth $390M, up 3.3% from $378M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Parkman Healthcare Partners withdrew a net $64M in Q4 2020, closing 17 positions and reducing 38 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Technology.

Against the trend, Parkman Healthcare Partners opened a new position in Avantor worth $4.25M.

  • Parkman Healthcare Partners's largest Q4 2020 buy was Avantor: 150,872 shares worth $4.25M.
  • Parkman Healthcare Partners added most to Schrodinger in Q4 2020, an estimated $6.67M increase.
  • Parkman Healthcare Partners's biggest Q4 2020 reduction was Edwards Lifesciences, cutting an estimated $5.97M.
  • Parkman Healthcare Partners fully exited Neurocrine Biosciences in Q4 2020, selling an estimated $12.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 30% of its $390M portfolio in Q4 2020.
  • Parkman Healthcare Partners opened 16 new positions and closed 17 in Q4 2020.
  • Parkman Healthcare Partners's portfolio value rose 3.3% quarter-over-quarter to $390M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2020, filed 12 Feb 2021.